Page last updated: 2024-10-15

8-epidiosbulbin e acetate

Description

8-epidiosbulbin E acetate: anti-bacterial agent and plasmid-curing compound isolated from Dioscorea bulbifera; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
DioscoreagenusA plant genus best known for edible underground tubers. Yam may also refer to a moist variety of sweet potato, IPOMOEA BATATAS.[MeSH]DioscoreaceaeThe yam plant family, of the order Liliales, has thick roots or tubers and net-veined, heart-shaped leaves that sometimes are lobed.[MeSH]

Cross-References

ID SourceID
PubMed CID134715250
CHEBI ID175936
MeSH IDM0528839

Synonyms (5)

Synonym
[(1r,2s,3s,5s,8s,10s,11r,13r)-8-(uran-3-yl)-10-methyl-6,15-dioxo-7,14-dioxatetracyclo[11.2.1.02,11.05,10]hexadecan-3-yl] acetate
8-epidiosbulbin e acetate
CHEBI:175936
91095-48-6
[(1r,2s,3s,5s,8s,10s,11r,13r)-8-(furan-3-yl)-10-methyl-6,15-dioxo-7,14-dioxatetracyclo[11.2.1.02,11.05,10]hexadecan-3-yl] acetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's7 (50.00)24.3611
2020's6 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]